Apnimed

44 articles about Apnimed

• Apnimed to Participate in the SVB Securities Global Biopharma Conference

  1/25/2023

  Apnimed, Inc. today announced that company management will participate in 1x1 investor meetings at the SVB Securities Global Biopharma Conference taking place virtually January 31- February 2, 2023.

• Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea (OSA)

  1/3/2023

  Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea and related disorders, announced that it has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million.

• Apnimed to Present at the Stifel Healthcare Conference

  11/8/2022

  Apnimed today announced that management will participate in the Stifel Healthcare Conference taking place November 15-16, 2022 in New York.

• Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)

  10/17/2022

  Apnimed announced positive topline results from the MARIPOSA Phase 2b trial, an efficacy, safety and dose-finding study of one-month duration.

• Apnimed to Participate in the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum

  10/12/2022

  Apnimed today announced that company management will participate in the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum taking place October 18-19, 2022.

• Apnimed Expands Senior Leadership Team by Appointing John Cronin, M.D., Senior Vice President, Clinical Development

  10/5/2022

  Apnimed today announced that John Cronin, M.D., has joined the company as Senior Vice President, Clinical Development.

• Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference

  8/4/2022

  Apnimed announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022.

• Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA)

  6/28/2022

  Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA).

• Apnimed Adds Ruoxi Hu, Ph.D., From Morningside Technology Advisory to Its Board of Directors

  6/16/2022

  Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that Ruoxi (Rosy) Hu, Ph.D., from Morningside Technology Advisory, LLC has been appointed to the company’s Board of Directors.

• Apnimed to Present at the Jefferies Healthcare Conference

  6/6/2022

  Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced that Apnimed will participate in the Jefferies Healthcare Conference taking place June 8-10, 2022, and invites investors to view the live presentation and participate in one-on-one meetings.

• Apnimed Announces $62.5 Million Series C Financing to Advance Development of Novel Pharmaceutical Treatments for Obstructive Sleep Apnea (OSA) and Related Sleep Disorders

  5/4/2022

  Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, announced that it has raised $62.5 million of committed capital in a Series C financing.

• 

  Money on the Move: April Showers Bring May Flowers—and Funding

  5/4/2022

  Dianthus Therapeutics, Enavate Sciences and CytoTronics were all launched with this recent wave of investor funding. For that and more, continue reading. 

• Apnimed to Participate in the 21st Annual Needham Virtual Healthcare Conference

  4/5/2022

  Apnimed announced that company management will participate in 1x1 investor meetings at the 21st Needham Healthcare Conference taking place virtually April 11-14, 2022.

• Apnimed to Present at the 32nd Annual Oppenheimer Healthcare Conference

  3/10/2022

  Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, announced that Apnimed will participate in the 32nd Annual Oppenheimer Conference taking place March 15-17, 2022 virtually, and invites investors to view the presentation via webcast and participate in virtual one-on-one meetings.

• Apnimed Study APC-004 Phase 2 Data to be Presented at World Sleep 2022

  3/9/2022

  Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced that data from its Phase 2 study APC-004 will be featured in an oral presentation at World Sleep 2022 in Rome, Italy on Monday, March 14.

• Apnimed to Participate in the SVB Leerink Global Healthcare Conference

  2/7/2022

  Apnimed announced that company management will participate in 1x1 investor meetings at the SVB Leerink Global Healthcare Conference taking place virtually February 14-18, 2022.

• Apnimed to Present at the 40th Annual JP Morgan Healthcare Conference

  1/6/2022

  Apnimed to Present at the 40th Annual JP Morgan Healthcare Conference.

• Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)

  12/16/2021

  Apnimed today announced the dosing of the first patient in the Phase 2b MARIPOSA study of AD109, the company’s lead investigational oral medication for the treatment of OSA.

• Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease

  10/13/2021

  Apnimed today announced positive data across multiple endpoints from its Phase 2 randomized, double-blind, placebo-controlled, crossover clinical trial (Study APC-004) evaluating the efficacy and safety of AD109 as a treatment for patients with mild to moderate OSA.

• Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment

  10/13/2021

  Apnimed today announced positive data across multiple endpoints from a Phase 2 randomized, double-blind, placebo-controlled, four-period, single-dose crossover factorial clinical trial (APC-003), and a 28-day open-label extension study, evaluating AD109 as a treatment in patients with mild to severe OSA.